Full-Time

Senior Manager

Development Outsourcing

Confirmed live in the last 24 hours

Vir Biotechnology

Vir Biotechnology

501-1,000 employees

Develops monoclonal antibodies for infectious diseases

Compensation Overview

$154k - $216k/yr

+ Bonus + Equity

Senior, Expert

No H1B Sponsorship

San Francisco, CA, USA

Onsite 4 days a week

Category
Public Health
Biology & Biotech
Required Skills
Financial analysis
Excel/Numbers/Sheets
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Vir Biotechnology referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • B.A./B.S. degree
  • 8-10+ years of relevant experience or equivalent
  • Negotiation and persuasion skills, both in one-on-one and group settings
  • Project management skills and ability to own initiatives from start to finish
  • Experience in budget analysis and presenting summary to senior leadership
  • Advanced Excel skills required
Responsibilities
  • Lead the vendor selection lifecycle including the management of Request-for-Information (RFI) and Request-for-Proposal (RFP) activities for clinical services
  • Manage the relationships with important vendor partners to enable collaboration and resolution of challenges
  • Independently lead strategic initiatives such as category refreshes and preferred partnerships to lead overall vendor strategy
  • Draft, implement, track and archive CDAs, MSAs, and other multiple vendor contract agreements following Vir's standards and processes
  • Negotiate and manage budgets, financial terms, refine scope and conduct analysis
  • Engage and partner with Clinical Operations, Legal, Regulatory, Finance and vendors, to enable informed, risk-considered decisions
  • Review invoices against contractual terms to ensure compliance and to identify conflicts or changes requiring resolution with contract revisions
  • Identify and help implement new or improved departmental processes or standards
  • Organize and lead meetings with internal staff, vendors and other third parties

Vir Biotechnology develops treatments for infectious diseases by harnessing the immune system. The company uses a proprietary platform for monoclonal antibodies and incorporates machine learning to create a database of human antibodies, which helps in developing effective medicines. Vir's pipeline includes candidates for hepatitis B, hepatitis delta, HIV, and various viruses like influenza and COVID-19. Their goal is to transform lives by addressing unmet medical needs through collaborations with industry leaders and organizations.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in AI-driven drug discovery benefits Vir's AI capabilities.
  • The rise of personalized medicine aligns with Vir's monoclonal antibody focus.
  • Global pandemic preparedness funding supports Vir's broad-spectrum antiviral therapies.

What critics are saying

  • Leadership instability due to key executive resignations may disrupt operations.
  • Job cuts and facility closures indicate potential financial strain.
  • Struggles to diversify beyond COVID-19 antibody success may impact revenue growth.

What makes Vir Biotechnology unique

  • Vir Biotechnology uses AI-enhanced capabilities for monoclonal antibody development.
  • The company focuses on immune system manipulation for targeted therapies.
  • Vir's pipeline includes a potential functional cure for chronic hepatitis B.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive healthcare coverage

Employer matched 401(k)

Employee stock purchase plan

Childcare assistance

Tuition reimbursement

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

2%
U.S. Securities and Exchange Commission
Dec 5th, 2024
vir-10q_20200331.htm

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Investing.com
Aug 1st, 2024
Vir Biotechnology inks major deal with Sanofi unit

Moreover, Vir Biotechnology has entered into a significant licensing agreement with Amunix Pharmaceuticals, Inc., a Sanofi company.

MarketScreener
Aug 1st, 2024
Vir Biotechnology to Cut 140 Jobs in Restructuring to Focus on Hepatitis Drug Development

Vir Biotechnology to cut 140 jobs in restructuring to focus on hepatitis drug development.

Simply Wall St
May 5th, 2024
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

Vir Biotechnology, Inc. (NASDAQ:VIR) just released its quarterly report and things are looking bullish.

Investing.com
Apr 18th, 2024
Vir Biotechnology CFO Sung Lee to step down in May

Vir Biotechnology Inc. (NASDAQ:VIR) announced Monday that Executive Vice President and Chief Financial Officer Sung Lee will resign from his position effective May 3, 2024.